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A Comprehensive Review of MDMA and GHB:  
Two Common Club Drugs
Christian J. Teter, Pharm.D., and Sally K. Guthrie, Pharm.D., FCCP
“Club drugs” have become alarmingly popular.  The use of 3,4-
methylenedioxymethamphetamine (MDMA, Ecstasy) and g-hydroxybutyrate
(GHB), in particular, has increased dramatically from 1997–1999.  The
pharmacokinetics of MDMA and GHB appear to be nonlinear, making it
difficult to estimate a dose-response relationship.  The drug MDMA is an
amphetamine analog with sympathomimetic properties, whereas  GHB is a g-
aminobutyric acid analog with sedative properties.  Symptoms of an MDMA
toxic reaction include tachycardia, sweating, and hyperthermia.  Occasional
severe sequelae include disseminated intravascular coagulation,
rhabdomyolysis, and acute renal failure.  Treatment includes lowering the
body temperature and maintaining adequate hydration.  Symptoms of GHB
intoxication include coma, respiratory depression, unusual movements,
confusion, amnesia, and vomiting.  Treatment includes cardiac and respiratory
support.  Because of the popularity of these agents and their potentially
dangerous effects, health care professionals must be familiar with these
substances and the treatment options for patients who present with symptoms
of a toxic reaction.
(Pharmacotherapy 2001;21(12):1486–1513)
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The increase in the popularity of a socially
designated class of drugs known as “club drugs”
has been alarming.  These drugs acquired this
label because they are used most often at all-
night dance parties known as “raves” or in dance
clubs and bars.  Drugs commonly included in
this group are 3,4-methylenedioxymetham-
phetamine (MDMA, “Ecstasy”), g-hydroxybutyrate
(GHB), flunitrazepam (“Roofies”), ketamine,
methamphetamine, and lysergic acid diethyl-
amide (LSD).  Many of these drugs are colorless,
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tasteless, and odorless and can be placed covertly
into beverages.  Therefore, some of these drugs,
in particular GHB and flunitrazepam, have been
used to intoxicate or sedate unsuspecting
individuals to facilitate sexual assault and have
been given the name “date rape” drugs.1
Epidemiologic studies have shown that use of
club drugs is on the rise.2, 3 According to the
Monitoring the Future Study,2 the use of MDMA
has risen sharply over the last couple of years.  In
2000, 8.2% of 12th graders reported taking
MDMA in the prior 12 months, an increase from
5.6% in 1999.  Use also increased markedly
among American college students, from 0.5% in
1994 to 5.5% in 1999.  According to the principal
investigator for the Monitoring the Future Study,
two reasons explain why MDMA use may still be
on the rise despite a great deal of attention in the
media.  First, young people may not yet see
MDMA as a dangerous drug.  Second, the
perceived availability of MDMA has increased
dramatically.  By 2000, 51% of 12th graders
stated that they could buy MDMA fairly or very
easily.  The same study reported that the
prevalence rates of GHB and ketamine use are
1–2.5% in grades 8, 10, and 12.  Ketamine and
GHB were added to the ongoing Monitoring the
Future Study in 2000, so it is not possible to
obtain usage trends for these drugs.  The use of
flunitrazepam, crystal methamphetamine, and
LSD has actually declined from peak levels in the
mid-1990s through 2000.
The increase in the use of club drugs has been
observed by medical care providers.  According
to the Drug Abuse Warning Network (DAWN)
report,3 emergency department episodes
significantly increased for MDMA (p<0.01), GHB
(p<0.01), and ketamine (p<0.05) from
1994–1999.  These increases were especially
dramatic from 1997–1999 for MDMA and GHB
(Figures 1 and 2).  Apparent increases in the use
of flunitrazepam over the same time period were
not statistically significant.  Methamphetamine
and LSD account for the largest number of
emergency department “mentions” in this report
overall; however, mentions of methamphetamine
dropped significantly from 1994–1999, whereas
mentions of LSD remained stable over these 6
years.  (A mention refers to a specific substance
that was mentioned in a drug abuse episode.)
The use of these drugs poses a serious public
health problem, and health care professionals
need to be familiar with these substances.
MDMA
History
The drug MDMA (Ecstasy, “E”) is a ring-
substituted amphetamine analog commonly
taken as a recreational drug of abuse.  It was
synthesized in 1912 by Merck Pharmaceuticals
and patented in 1914.4 However, MDMA did not
become popular until the 1970s when it was
promoted as a useful adjunct to psychotherapy.
It allegedly improved self-esteem and enhanced
communication within significant emotional
relationships.5 Therapeutic applications for
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Figure 2. Drug Abuse Warning Network (DAWN) statistics
of the number of emergency department mentions of g-
hydroxybutyrate (GHB) from 1994–1999. (From reference
3.)
Figure 1. Drug Abuse Warning Network (DAWN) statistics
of the number of emergency department mentions of 3,4-
methylenedioxymethamphetamine (MDMA) from
1994–1999. (From reference 3.)
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MDMA were not well established, however, and
the Drug Enforcement Administration (DEA)
classified MDMA as a schedule I drug in 1985
after its recreational use became more widespread
and publicized.6 It also was shown that 3,4-
methylenedioxyamphetamine (MDA), an analog
and metabolite of MDMA, had a neurotoxic effect
in animals.7
Availability
The drug MDMA is commonly distributed as
small tablets, capsules, or white powder.  Ecstasy
tablets may contain various chemicals other than
pure MDMA, including MDA, 3,4-methylene-
dioxyethylamphetamine (MDEA), caffeine,
dextromethorphan, ephedrine, phenyl-
propanolamine, methamphetamine, ampheta-
mine, diphenhydramine, ketamine, cocaine, and
diazepam.  Some have contained no active drugs
at all.8 Results of analyses of tablets from all over
the United Kingdom, given to the Leeds
Addiction Unit, confirm that there are many
ingredients in Ecstasy tablets other than MDMA.9
In another report, MDMA concentrations in 25
tablets varied 70-fold, and 9 of the tablets did not
contain either MDMA or any related MDMA
analog.10 Furthermore, MDMA tablets collected
by the Haight Ashbury Free Medical Clinic
contained from 16–150 mg of MDMA/tablet.
Owing to the great variability in the dose of
MDMA in any given tablet, it is very difficult for
users of MDMA to control their dose.  Larger-
than-expected doses of MDMA may be taken
accidentally, leading to adverse effects.11
Furthermore, because of the variety of substances
that may be found in any given MDMA tablet, the
clinical presentation of acute intoxication may
vary significantly.
Chemistry
The chemical designation of MDMA is N-
methyl-1-(3,4-methylenedioxyphenyl)-2-
aminopropane (Figure 3).  Structurally it
resembles both the stimulant amphetamine and
the hallucinogen mescaline.12 The drug MDMA
is optically active, with the dextrorotatory isomer
(S+) having higher central activity than the
levorotatory isomer.4, 13
Pharmacokinetics
Pharmacokinetic Parameters
The pharmacokinetics of MDMA after oral
ingestion have been studied by various
researchers.14–17 The time to maximum
concentration (Tmax) is 2 hours after oral
ingestion of MDMA 50, 75, or 125 mg.14–17 The
half-life shows little variation after a wide range
of doses.  After a 50-, 75-, or 125-mg dose, the
half-life is 8 hours.16, 17 Other studies found the
half-life to be 9.53 hours after a 75-mg dose and
9.12 hours after a 125-mg dose.14 The maximum
1488
Figure 3. Mechanism of MDMA elimination.  The parent compound MDMA and its metabolites are excreted in the urine to
varying degrees (see text).  Also, MDMA may be metabolized by ring hydroxylation and demethylenation to potential
serotonergic neurotoxins.
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concentration (Cmax) after oral ingestion appears
to be dose dependent.  A Cmax of 105.6 ng/ml was
reported in a single subject who took a 50-mg
dose,16 whereas a Cmax of 330 ng/ml was found in
another subject who took MDMA 135 mg.18 In a
group of eight subjects, the Cmax values after
ingestion of MDMA 75 mg and 125 mg were
126.5 and 226.3 ng/ml, respectively,14 whereas in
another group of eight subjects, Cmax values of
130.9 ng/ml and 236.4 ng/ml were obtained after
ingestion of MDMA 75 mg and 125 mg,
respectively.17 In these studies, the Cmax exhibits
a slightly greater-than-expected increase
compared with the increase in dose.  According
to these observations, after the usual recreational
dose of 100–150 mg, the Cmax should be 200–300
ng/ml.  The area under the concentration-time
curve (AUC) data from these studies also suggest
nonlinearity.  The AUC measured over 24 hours
after ingestion of a 125-mg dose (2235.9
µg/L•hr) is more than twice the AUC after
ingestion of a 75-mg dose (995.4 µg/L•hr).14
Nonlinearity is further supported by other
evidence, in which the dose ratio of MDMA was
1:3 (50 mg and 150 mg), whereas the AUC ratio
over 24 hours after ingestion was greater than
1:10.  The authors suggested that the nonrenal
clearance of MDMA is dose dependent (i.e.,
HMMA, one of the many metabolites of MDMA
metabolism [Figure 3], was the major product in
plasma at lower doses, whereas MDMA was the
predominant product at higher doses).  This
resulted in a disproportionate increase in plasma
AUC and an increase in the proportion of MDMA
excreted in the urine as the dose increased.  It is
possible that demethylenation may be inhibited
as MDMA accumulates or one of the MDMA
metabolites may inhibit cytochrome P450 (CYP)
2D6, which is responsible for a substantial
proportion of MDMA nonrenal clearance.
Alternatively, there might be an increase in the
fraction of drug bioavailable as the dose
increases.15 Unfortunately, to our knowledge, the
oral bioavailability of MDMA has not been
determined in humans.
Primary Metabolism
The primary metabolic pathways for MDMA
have been elucidated, with a number of
metabolites having been identified in both
animals and humans (Figure 3).  The main meta-
bolic pathway appears to be demethylenation to
the catechol metabolite 3,4-dihydroxy-
methamphetamine (DHMA; also called N-
methyl-a-methyldopamine).19 The metabolite
DHMA is the major metabolite of MDMA in rat
liver19, 20 and in rat brain microsomes.21
Microsomes from yeast expressing human
CYP2D6 demethylenate MDMA to the metabolite
DHMA.22, 23
Furthermore, using human liver microsomes,
CYP2D6 is the primary isoenzyme responsible
for the demethylenation of MDMA.24 If CYP2D6
is the isoenzyme responsible for the majority of
MDMA metabolism in humans, then poor
metabolizers could be sensitive to the acute
physiologic effects of MDMA, but less prone to
any long-term toxic effects of MDMA arising
from metabolites.  However, case reports have
indicated that fatal MDMA intoxications have
occurred in patients who were shown to be
CYP2D6 extensive metabolizers,25 and it also has
been shown in vivo that in the absence of
functional CYP2D6 a considerable amount of
metabolism of MDMA analogs occurs by
demethylenation.24 It may be that more than one
metabolic pathway can lead to an MDMA-
induced toxic reaction.
Secondary Metabolism
A second pathway of MDMA metabolism is N-
demethylation to MDA, which appears to be a
minor metabolite of MDMA14 and is an abused
drug in its own right.  Concentrations of MDA in
plasma range from 3–5% of those corresponding
to MDMA.14 When formed from MDMA, the
MDA formation rate constant is approximately
0.75/hour and the half-life is 16–28 hours,
depending on the dose of MDMA given.  The
Cmax for MDA occurs at 5–7 hours, and, on the
basis of plasma AUC comparisons of MDMA and
MDA, 8–9% of MDMA is converted to MDA,
which may be further metabolized before
elimination.  The urinary recovery of unchanged
MDA accounts for approximately 1% of the dose
of MDMA.17 It is unlikely that significant
accumulation of MDA would occur after a single
dose of MDMA.  Given the prolonged half-life of
MDA, however, it could accumulate in an
individual taking MDMA 3 or more times/week.
Toxic Metabolites
It has been hypothesized that some of the
neurotoxic actions of MDMA may result from
quinones formed from the metabolism of DHMA,
which can combine with glutathione and other
thiol compounds.19, 22 A 6-hydroxy-dopamine
analog is formed by the aromatic hydroxylation
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and demethylenation of MDMA that also could
be neurotoxic.22, 26 Catecholamines formed from
MDMA, such as DHMA, are highly polar
compounds that cannot cross the blood-brain
barrier.  However, these highly polar compounds
have been detected in the brain after peripheral
administration of MDMA,27 indicating that some
MDMA metabolism may occur in the brain.
Drug Interactions
There is a single report, to our knowledge, of a
possible drug interaction involving MDMA and
ritonavir.28 A patient receiving ritonavir for the
treatment of human immunodeficiency virus
ingested MDMA in an estimated dose of 180 mg.
The resultant blood MDMA level was 4.56 µg/ml,
which is much higher than would be expected
from this dose of MDMA.  The authors suggest
that the coadministration of MDMA and ritonavir
(an inhibitor of CYP2D6) is the explanation for
the unusually high levels of MDMA after a
commonly used recreational dose.28
Preincubation of MDMA with human liver
microsomes and nicotinamide adenine
dinucleotide phosphate (NADPH) resulted in
significant inhibition of CYP2D6 activity.
Therefore, MDMA may be a potent inhibitor of
CYP2D6 in vivo, and the interaction of MDMA
with this metabolic pathway may cause long-
lasting drug interactions with other CYP2D6
substrates.29 No clinical data are available in
support of this theory.
Elimination
In humans, approximately 50–70%15, 16 of the
total MDMA dose is recovered in the urine as
MDMA and other metabolites.  Although MDMA
is metabolized in the body, a large proportion is
excreted unchanged in the urine.  A report based
on one patient indicated that after a single oral
ingestion of MDMA 50 mg, 32.52 mg (65%) of
unchanged drug was excreted in the urine over
72 hours.16 In another study,15 urine collection
showed an increase in the amount of unchanged
MDMA excreted by a factor of 20, from the 50-
mg to the 150-mg dose, whereas the urinary
recovery of 4-hydroxy-3-methoxymetham-
phetamine (HMMA), a metabolite of MDMA
metabolism, remained unchanged.  No
significant changes in the urinary pH or
creatinine clearance occurred during this study.
Although the renal clearance remained fairly
constant, the nonrenal clearance appeared to be
dose dependent.15
Pharmacology
Receptor Biochemistry
The drug MDMA is a potent indirect
monoaminergic agonist, which is thought to act
by both increasing the release and inhibiting the
reuptake of serotonin and, to a lesser extent,
dopamine.30 Serotonin is involved in the
regulation of a variety of behavioral functions,
including mood, anxiety, aggression, appetite,
and sleep.  Dopamine is the primary neuro-
transmitter of the “reward pathway” and is
involved in motivational processes such as
reward and reinforcement.  Norepinephrine has
important roles in the processes of attention and
arousal.  In vitro, MDMA causes release of
serotonin, dopamine, and norepinephrine from
synaptosomes31, 32 and rat brain slices.33, 34 In
vivo, in freely moving rats, MDMA increases both
serotonin and dopamine release in the caudate.35
In a similar study, MDMA increased dopamine
release in vivo in awake rats, resulting in region-,
time-, and dose-dependent behavior.36 In rat
brain synaptosomes, MDMA inhibited the uptake
of serotonin and norepinephrine and, to a lesser
extent, dopamine.37 The local administration of
MDMA to the rat nucleus accumbens resulted in
increases in the extracellular levels of both
serotonin and dopamine in this region,38 which is
part of the reward pathway activated by other
abused substances such as amphetamine and
cocaine.  These actions in the nucleus accumbens
may account for the euphoric effects produced by
MDMA.
In addition to causing the release of serotonin
and inhibiting its reuptake, MDMA may have
direct agonist effects on serotonin and dopamine
receptors.39 It has affinities for a broad range of
neurotransmitter recognition sites39, 40 and may
act at both serotonin receptors, 5-HT2A and 5-
HT2C.41 Selective serotonin reuptake inhibitors
(SSRIs) such as fluoxetine and citalopram block
the release of serotonin induced by MDMA, both
in vitro42, 43 and in vivo.44, 45 They also reportedly
block the subjective effects produced by MDMA
in humans.46 Consequently, the release of
serotonin by MDMA may be dependent on the
serotonin transporter.  Different potencies for the
neurotransmitter systems are shown by MDMA
than by either amphetamines or the
hallucinogens.  Owing to its individual
biochemical profile and the subjective effects it
produces in humans, MDMA has been called an
entactogen, which means, “producing a touching
within.”13
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Abuse Liability and Psychomotor Performance
In controlled studies, MDMA produced marked
feelings of euphoria and well-being47, 48 and
possessed amphetamine-like properties.47
Indexes of positive psychologic states have been
shown to increase with increasing MDMA
dosage.49 Subjective effects peak between 90
minutes and 2 hours after ingestion of MDMA
and return to baseline approximately 4 hours
after ingestion.47 The drug MDMA produces
mild changes in perceptions but does not
commonly cause hallucinations or psychotic
episodes.47 It also produces moderate derealization
and depersonalization, as well as anxiety without
marked increases in psychomotor drive.48
Cardiovascular Effects
Ingestion of MDMA 75 and 125 mg causes an
increase in blood pressure and heart rate, which
occurs maximally at 90 minutes and 60 minutes,
respectively.17 Marked increases in blood
pressure and heart rate have been seen after doses
of MDMA 0.25–1.0 mg/kg49 and 1.7 mg/kg,
respectively.48 In the latter investigation, peak
increases in blood pressure occurred 2 hours
after drug administration, and 12 of the 13
subjects had a peak blood pressure of 160/100
mm Hg, whereas blood pressure in the last
patient peaked at 240/145 mm Hg.48
Neuroendocrine Effects
Plasma cortisol levels are significantly
increased after ingesting MDMA at both 75 and
125 mg, and the 125-mg dose causes significant
elevations in prolactin levels as well.  The
increases in cortisol and prolactin levels reach a
peak at 2 hours after MDMA administration.17
Other findings state that adrenocorticotropic
hormone (ACTH) and prolactin concentrations
are increased after the oral administration of
MDMA 0.75–1.0 mg/kg49 and that increases in
serotonergic function increase both cortisol and
prolactin levels.  For example, fenfluramine, a
drug that causes serotonin release, produces
dose-related increases in the concentrations of
both cortisol and prolactin.50 In addition to
cortisol and prolactin, plasma vasopressin
(arginine vasopressin [AVP]) is significantly
elevated 1–2 hours after MDMA administration,
which may be accompanied by a small decrease
in serum sodium levels and unchanged cortisol
levels.  Therefore, the slight hyponatremic effect
could be related to the ability of MDMA to
release AVP rather than a stress response, as
elevated AVP levels may be accompanied by
unchanged cortisol levels.51 However, similar
doses caused significant elevations in ACTH in a
study by a different group of researchers.49
Ocular Effects
Ingestion of MDMA 75 and 125 mg produces
significant mydriasis, with a maximal change in
pupillary diameter occurring 1–2 hours after
drug administration.  Furthermore, MDMA 125
mg produces significant esophoria (tendency for
the eyes to turn inward).47
Compound Lethality
The lethality of a compound (LD50) is the dose
of a drug that will kill 50% of the animals
receiving that dose.  Work done by the U.S. Army
in 1953–1954 compared the 24-hour LD50 among
five different animals (mice, rats, guinea pigs,
dogs, and monkeys).  Of the five known human
hallucinogens that were tested, MDMA was the
second most toxic agent.52 The LD50 was 49
mg/kg in rats, 14 mg/kg in dogs, and 22 mg/kg in
rhesus monkeys.  It is difficult to extrapolate
these data to humans because the animal data
were obtained after intravenous or intraperitoneal
administration, and MDMA is taken orally (its
oral bioavailability in humans is unknown).
However, these findings indicate that MDMA
causes a significant dose-dependent toxic
reaction and death in many animals.
Preclinical Neurotoxic Reactions
In animals, extensive data describe MDMA-
induced neurotoxic effects to the serotonergic
system.53 Dose-related reductions in brain levels
of both serotonin and its major metabolite, 5-
hydroxyindoleacetic acid (5-HIAA), are caused
by MDMA in the rat,54–56 guinea pig,56 and
monkey.57–59 The activity of tryptophan
hydroxylase, which is the rate-limiting enzyme in
the synthesis of serotonin, is decreased after
MDMA administration.55, 60, 61 Reductions in the
density of serotonin uptake sites have been
noted.56, 62, 63
Furthermore, immunocytochemical studies,
which provide visualization of the serotonergic
axons, have shown neurodegenerative changes
including swollen, fragmented serotonin axons,
with the fine serotonin axon terminals being
especially vulnerable to the toxic effects of
MDMA.64–66 One study found a marked reduc-
tion in the number and density of serotonin-
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immunoreactive axons throughout the cerebral
cortex in monkeys who also displayed reductions
in brain concentrations of serotonin and 5-HIAA.
This is important as it provides some evidence
that reductions in serotonin and 5-HIAA may be
directly associated with morphologic findings of
damage to serotonergic axons.59
In one study that used positron emission
tomography (PET) in the nonhuman primate,67 a
substantial loss of serotonin transporters was
found in the central nervous system (CNS) after
MDMA treatment. Reasonably good agreement
was noted between the PET data and reductions
in serotonin, 5-HIAA, and serotonin transporter
density, measured neurochemically in postmortem
brain tissue 3 weeks after the last PET study was
performed.67 The neurotoxic effects of MDMA
on the serotonergic system of the monkey may be
long-lasting and still evident from 18 months68 to
7 years69 after the administration of MDMA.
There is evidence of some regrowth of the axons,
but it may be abnormal and incomplete,69 with
some reorganization of ascending serotonergic
projections.70
Clinical Neurotoxic Reactions
In addition to the extensive animal data
providing evidence for serotonergic neurotoxic
effects, there is evidence of possible neurotoxic
reactions in human users of MDMA.  The
serotonergic neurotoxic evidence can be
classified into three domains:  neurobiologic (i.e.,
neuroendocrine and brain imaging), psychologic
and somatic, and psychiatric.
Neurobiologic Domain
Studies have shown dose-dependent decreases
in the concentrations of the serotonin metabolite
5-HIAA in the cerebrospinal fluid of individuals
taking MDMA.71, 72 Another technique to assess
serotonergic damage in humans is to administer
serotonergic agonists and examine neuro-
endocrine responses.  Various serotonergic
agonists such as L-tryptophan, m-chlorophenyl-
piperazine (m-CPP), and D-fenfluramine (D-fen)
have been used to assess the prolactin response.71,
73–75 Two studies evaluated the prolactin response
after the administration of L-tryptophan, a
serotonin precursor known to increase serum
prolactin concentration.  One investigation found
a nonsignificant trend toward a blunted prolactin
response in those who took MDMA, as compared
with control subjects,74 whereas the other study
did not find significant differences in the
prolactin response to L-tryptophan in those who
last took MDMA 18 weeks–2 years before the
beginning of the study, in comparison with the
control group.71 With use of m-CPP, 25
individuals who took MDMA were less sensitive
to the anxiogenic effects of m-CPP compared
with 25 controls, and the men who took MDMA
had a diminished prolactin and cortisol response
to m-CPP.73 A blunted neuroendocrine response
also was found with the serotonin releaser, D-fen,
in 15 individuals abstaining from taking MDMA
in comparison with control subjects.  Prolactin
response to D-fen was significantly reduced in
individuals taking MDMA at both 3 weeks and
12 months after last MDMA use.  In contrast,
cortisol response to D-fen was reduced at 3 weeks
but had recovered by 12 months in those taking
MDMA.  The authors suggest that the cortisol
response at 12 months may indicate either partial
recovery to the neurotoxic actions of MDMA or
selective neurotoxic actions of MDMA on
different serotonin receptors and pathways.75
A study using PET with [11C] McN5652 (a
radioligand selective for the 5-HT transporter)
found that individuals who abstained from taking
MDMA (at least 3 weeks since last use) showed
significant reductions in 5-HT transporter
binding compared with that of control subjects
who had never taken MDMA.  This was
attributed to a reduced density of serotonin
uptake sites.  Furthermore, reduced binding was
positively correlated with the amount of previous
MDMA use.76 Another study using PET imaging
found a reduction in the brain glucose
metabolism in individuals taking MDMA.  The
PET scans were obtained in seven individuals
who had taken MDMA from 1–39 months and
seven age-matched control subjects with no
history of illicit drug use.  Glucose uptake was
lowered in the hippocampus, amygdala, and
cingulate bilaterally in the MDMA group.77 A
decrease in the density of serotonin uptake sites
has been found with use of other brain imaging
techniques as well.  Ten men who had taken
MDMA long term were compared with 10
individuals who had not taken MDMA, matched
for the consumption of other drugs.  Each
subject was examined with single photon
emission computed tomography (SPECT) with a
5-HT transporter ligand.  The MDMA group
showed a reduction in cortical serotonin
transporter binding.78 In another SPECT study,79
cortical 5-HT2A receptor densities in the occipital
cortex were increased in five individuals who
abstained from taking MDMA (at least 2 months
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since last use) compared with nine healthy
control subjects.  The authors suggested an
upregulation of postsynaptic 5-HT2A receptors
due to serotonin depletion.80 Only the subjects
with apparent high densities of postsynaptic 5-
HT2 receptors in the occipital area showed
detectable decreases in memory function.
Psychologic and Somatic Domain
Memory decrements are more pronounced in
those taking MDMA regularly (10 or more
occasions) than in those just beginning (9 or
fewer occasions).81 In addition, both those just
beginning to take MDMA and those regularly
taking MDMA exhibit significantly lower
immediate word recall and delayed word recall
compared with control subjects.81 Significant
memory impairment has been reported in those
who take only MDMA compared with those who
take many drugs but who had never taken
MDMA, suggesting that the memory impairments
are caused primarily by the MDMA rather than
the various other drugs consumed by these
individuals.82
Psychiatric Domain
Two studies suggest a depression of mood in
the days after taking MDMA.83, 84 In one study,
those who took MDMA scored in the mild-to-
moderate clinical range for depression on the
Beck Depression Inventory.83 In the other study,
visual analog mood scales were used to assess 16
mood states.  Those taking MDMA reported
feeling significantly more depressed, abnormal,
unsociable, unpleasant, and less good tempered 2
days after the ingestion of MDMA than did the
control subjects.84 
Subjective Effects
There are very few controlled studies
evaluating MDMA in humans, mostly because
MDMA is a schedule I drug in the U.S. and
therefore is difficult to obtain for study purposes.
Also, the safety of human research subjects who
take MDMA cannot be guaranteed.  The
information that is available, with the exception
of a few small controlled trials, comes from
information collected retrospectively from people
who have taken MDMA outside of a controlled
research environment.  The high rate of concurrent
multisubstance abuse, the uncontrolled content
of active MDMA in any given pill, as well as the
historical accuracy of information reported by the
person who takes recreational drugs lend some
uncertainty to the conclusions drawn from these
reports.  According to these reports, MDMA is
ingested orally in a dose of approximately
100–150 mg, with an onset of effects usually
around 30 minutes, which is described as an
amphetamine-like rush.
The earliest reports of MDMA effects were
primarily anecdotal.  Although users stressed the
positive feelings associated with MDMA, negative
effects were also reported.  Some of the positive
effects include a sense of “closeness” toward
others, heightened alertness, increased ability to
interact with others, decreased defensiveness,
decreased fear, decreased sense of alienation from
others, increased awareness of emotions,
decreased aggression, euphoria, increased energy,
and sexual arousal.85–87 The negative effects
include tachycardia, trismus (jaw clenching),
bruxism (teeth grinding), decreased appetite,
lower back pain, and decreased desire to perform
mental or physical activities.85–87 Aftereffects
(“hangover”) most often described by those who
have taken MDMA include lethargy, anorexia,
decreased motivation, sleepiness, depressed
mood, and fatigue.85, 86 Of interest, many of the
subjects reported that with regular MDMA usage
( ‡ six separate doses), the positive effects
lessened while the negative effects increased.85
Consequently, many individuals space their
usage.5
Two early reports on the effects of MDMA were
prospective studies, involving 50 patients, that
were completed before the government
restriction of MDMA to schedule 1.5, 88 In both
studies, patients provided positive and negative
descriptions of the experience.  The positive
experiences included a perception of enhanced
communication, increased feelings of intimacy,
cognitive enhancement, euphoria, increased self-
confidence, a heightened sense of sensual
awareness (with some subjects reporting
increased sexual arousal and an increase in
physical and emotional energy).  Adverse effects
that were described by all of the subjects include
those similar to amphetamines such as tachycardia,
dry mouth, palpitations, bruxism, trismus,
nausea, anorexia, headaches, eyelid twitches, and
insomnia.  Unlike with amphetamines, there
appeared to be no “crash” or depression up to 24
hours after ingestion.5, 88
Pharmacologic Pretreatment
Three studies have investigated the feasibility
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of giving pharmacologic agents to block or
attenuate MDMA effects.  Citalopram is a
serotonin reuptake inhibitor that should block
the uptake of MDMA into the neuronal terminal.
Pretreatment with intravenous administration of
citalopram 40 mg attenuated the acute
psychologic effects of MDMA 1.5 mg/kg in
healthy volunteers.  Some of the effects
attenuated by citalopram included MDMA-
induced increases in positive mood, derealization
and depersonalization phenomena, and the loss
of thought and body control.  The attenuation of
the psychologic effects induced by MDMA as a
result of citalopram pretreatment suggests that
MDMA actions are at least partly dependent on a
carrier-mediated release of serotonin.46 The same
investigators performed another study designed
to test the effect of haloperidol 1.4 mg
intravenously (dopamine D2 antagonist) on the
psychologic and physiologic responses to
MDMA.  Haloperidol treatment before MDMA
administration reduced the positive mood and
euphoria induced by MDMA, but not the
cardiovascular effects.  The authors suggested
that there may be a role for dopamine in the
euphoria-producing effects of MDMA and that
serotonin or norepinephrine may mediate the
physiologic effects.89 The final study, also by this
group, used ketanserin (5-HT2 antagonist) to
examine the role of 5-HT2 receptors on MDMA’s
actions.  Ketanserin 50 mg was given orally to
healthy volunteers before the oral administration
of MDMA 1.5 mg/kg.  Ketanserin attenuated
perceptual changes and emotional excitation
induced by MDMA but had little effect on
MDMA-induced positive mood, well-being, and
extroversion.  Furthermore, body temperature
was lower after the MDMA-ketanserin
combination than with MDMA alone.90
Adverse Effects and Acute Toxic Reactions
Acute Syndrome
One of the dangers of MDMA is the apparent
lack of relationship between alleged dose and
severity of acute toxic reaction.91, 92 Although
one person attempted suicide after reportedly
taking 42 pills of Ecstasy with a resultant plasma
MDMA level of 7.72 µg/ml and displayed only
hypertension and tachycardia,93 others have died
with much lower plasma MDMA levels ranging
from 0.05–1.26 µg/ml.91 Furthermore, serum
MDMA levels do not correlate well with clinical
symptoms.94 Acute toxic reactions usually
develop within 15 minutes–6 hours after the
ingestion of MDMA.91 Symptoms of an acute
MDMA toxic reaction include agitation,
tachycardia, hypertension, dilated pupils,
trismus, and sweating, whereas the more severe
cases may be characterized by hyperthermia,
disseminated intravascular coagulation (DIC),
rhabdomyolysis, and acute renal failure.93 In
more severe cases, elevated creatine kinase levels
are often present,95–98 with levels as high as
122,341–555,000 IU/L being reported.97, 98 Other
frequently reported acute adverse effects
occurring after the ingestion of MDMA include
lack of appetite, difficulty concentrating,
impaired balance, and restless legs.48
The toxic effects of MDMA were divided into
three categories in one investigation to help
distinguish acute toxic reactions from long-term
residual effects.  These categories were acute
reactions at therapeutic doses, overdose
reactions, and residual effects.11 At moderate
doses (85–100 mg), acute effects included
transient nausea occurring about 30 minutes
after ingestion and lasting about 30 minutes,
increases in both blood pressure and heart rate,
and symptoms related to increased muscle
tonicity, such as jaw clenching and teeth
grinding.  In those subjects who were particularly
sensitive to MDMA, higher doses ( ‡ 100 mg)
caused numbness and tingling in the extremities,
luminescence of objects, increased sensitivity to
cold, increased color acuity, and vomiting.
Residual effects occurring from 2 hours–2 weeks
after ingestion included exhaustion, fatigue, and
nausea.  Doses higher than 200 mg result in a
classic toxic psychosis with symptoms of
paranoia and auditory and visual hallucinations.
Hyperthermia
Hyperthermia (temperature > 40°C) is the
most common adverse effect associated with a
severe acute toxic reaction to MDMA.  The
increase in body temperature is probably due to
serotonergic actions of MDMA in the thermo-
regulatory center in the hypothalamus99 because
animal studies have shown that the hyperthermia
caused by compounds such as MDMA is
mediated by actions at serotonin receptors in the
CNS.100 Hyperthermia also may be caused by
excessive heat production due to sustained
muscle hyperactivity, increased metabolic rate,
rigidity, and seizures.101 Hyperthermia is believed
to be the beginning of the cascade leading to
DIC, rhabdomyolysis, myoglobinuria, and acute
renal failure.  However, the exact pathophysiology
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of this cascade after MDMA intoxication has not
been fully elucidated.
Cardiovascular Effects
Similar to cocaine and amphetamine, MDMA
may cause sympathetic stimulation and increase
myocardial oxygen demand, leading to varying
degrees of tachycardia, vasoconstriction, changes
in blood pressure, and arrhythmias.  In severe
cases, vasospasm leading to acute myocardial
infarction and irreversible dilated cardio-
myopathy may occur.102 Abnormal electro-
cardiographic changes that show widespread ST
segment elevation indicating acute myocardial
infarction have been seen with laboratory
evidence in the urine of MDMA users.103 During
postmortem evaluations, necrosis of the heart
(contraction band necrosis or widespread foci of
necrosis) has been seen104 and may be due to
excessive catecholamines.102 These findings do
not necessarily establish a cause and effect
relationship, since other substances or
circumstances may have contributed.
Cerebrovascular Effects
“Designer drugs” such as MDMA are associated
with intracerebral hemorrhage, often in
conjunction with an underlying vascular
malformation.105 Other investigators have
postulated that those who take MDMA are at an
increased risk for cerebrovascular accidents due
to the altered 5-HT system because postsynaptic
5-HT receptors are involved in the regulation of
the brain microvasculature.106 Other cerebro-
vascular adverse effects that have been associated
with MDMA include subarachnoid hemorrhage,
cerebral infarction, and cerebral venous sinus
thrombosis.107 Magnetic resonance imaging
revealed a left basal ganglia hematoma after the
ingestion of MDMA in a patient with no apparent
cardiovascular risk factors.108
Neuroendocrine Effects
Numerous cases of hyponatremia have been
associated with MDMA use, often in combination
with seizures, catatonic stupor, and incontinence
of urine.109–114 It is possible that hyponatremia is
a direct result of MDMA neuroendocrine effects
or from massive water intake leading to
dilutional hyponatremia.  Since many users take
MDMA during all-night dancing parties, large
amounts of fluid are ingested, both as a natural
consequence of physical activity and because of
MDMA-induced hyperthermia.  Hyponatremia
may be due to the syndrome of inappropriate
antidiuretic hormone,111, 112 because MDMA
causes the release of AVP.51 In addition, the
extreme dehydration caused by sweating and/or
vomiting associated with MDMA use combined
with massive water intake could lead to
hyponatremia.115 In one report of a fatality due
to MDMA, hyponatremia leading to cerebral
edema appeared to be the main cause of death.116
Contamination of the MDMA tablets with other
substances has been postulated as the cause of
hyponatremia associated with MDMA use.110
Postcards have been distributed in some clubs
and bars advising patrons who take MDMA that
they should drink about a pint of water an hour
and eat or drink something salty, such as a sports
drink, to replace lost sodium.117
Hepatotoxicity
Hepatotoxic effects have been associated with
MDMA.91, 93, 104, 118, 119 In one case series of seven
fatalities associated with the use of ring-
substituted amphetamines, including MDMA,
necrosis of the liver was seen in all cases.104 Two
of the most likely mechanisms for causing a
hepatotoxic reaction are immune-mediated
reaction or injury secondary to hyperthermia.119
Hepatotoxic reaction arising from drug
impurities or MDMA metabolites is also possible.
Liver transplantation has been required because
of hepatic damage associated with MDMA use.118
Psychopathology
A psychotic syndrome characterized by
delusions, usually of the persecutory type, may
be caused by MDMA.  Other nonpsychotic
conditions include visual phenomena,
depersonalization and derealization, panic
attacks, and depression.  Persons who display
such symptoms may have at least one first-degree
relative with a history of psychiatric illness and
be predisposed to have psychiatric symptoms.120
Anxiety attacks, persistent insomnia, rage
reactions, and psychosis (especially at higher
doses) have occurred after MDMA use, although
in most cases the premorbid psychiatric status of
these patients was not known.11 Compared with
control subjects who do not take MDMA, those
who frequently take MDMA have significantly
higher scores on scales used to assess
somatization, obsessionality, anxiety, hostility,
phobic-anxiety, paranoid ideation, psychoticism,
poor appetite, and restless or disturbed sleep.
They also showed greater impulsiveness.121
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Death
Conditions commonly contributing to death
due to MDMA include dehydration, hyper-
thermia, disseminated intravascular coagulation,
rhabdomyolysis, acute renal failure, tachycardia
and other cardiac arrhythmias, and convulsions.93,
122 In other fatal cases involving MDMA, necrosis
of the liver and heart were found at autopsy as
were various injuries to the brain such as focal
hemorrhages and severe cerebral edema
consistent with water intoxication.104
Treatment
The diagnosis of acute toxic reaction to MDMA
is made based on the history and clinical features
of intoxication.  Initial examination should
include blood chemistry analysis, complete blood
count, liver function tests, cardiac enzyme and
creatine kinase measurements, and a urine
toxicology screen.  Quantitative serum levels do
not correlate well with severity of symptoms and
are not generally available.94 A complete history
and physical examination should be performed,
and the patient should be assessed for hyper-
tensive crisis or life-threatening arrhythmias.  An
electrocardiogram for chest pain or a computed
tomographic (CT) scan of the brain for persistent
mental status changes should be obtained.123, 124
Amphetamines and related drugs (i.e., metham-
phetamine, MDMA) can be detected in the urine,
but there is a high degree of cross-reactivity
between amphetamine derivatives and adrenergic
amines.  Therefore, confirmatory testing usually
is required.94
Resuscitation
There is no antidote for MDMA intoxication,
and in general, recommended treatment of
MDMA overdose is similar to the treatment of
amphetamine or methamphetamine overdose.
The first priority should be maintaining the
airway, breathing, and circulation.123, 124
Treatment will then be aimed at reducing various
symptoms, including hyperthermia, agitation,
cardiovascular and cerebrovascular incidents,
neuroendocrine abnormalities, and neurologic
problems.
Decontamination and Elimination
Decontamination of the gastrointestinal tract
with lavage, activated charcoal, and cathartic
techniques has been used.  Induction of emesis is
not appropriate because of the potential for CNS
depression and seizures.94 Because approxi-
mately 50–70%15, 16 of MDMA is recovered in the
urine, renal failure would significantly decrease
the elimination of MDMA from the body, so
maintaining adequate hydration is essential.
Because MDMA is a weak base and a significant
proportion is eliminated in the urine, acidifying
the urine is likely to be an effective means of
increasing renal elimination, but it may
precipitate acute renal failure in patients with
myoglobinuria and is not recommended.94
Hyperthermia
Although fatalities may be due to many
different causes, hyperthermia is probably the
single most important condition to treat because
it may lead to further severe complications, such
as rhabdomyolysis and DIC.125 Mortality has
been correlated to both the extent of hyper-
thermia and the duration, and active cooling
measures are indicated in cases of MDMA-
induced hyperthermia (see Supportive Care
section).99 It is important to control agitation to
limit further heat production.126 Neuromuscular
blockers, such as pancuronium, have been given,
but their use requires ventilation and
endotracheal intubation.94
Dantrolene sodium, a drug that is indicated for
the treatment of malignant hyperthermia and that
inhibits the release of calcium from the
sarcoplasmic reticulum, is recommended by
many clinicians to treat hyperthermia secondary
to MDMA use.93, 95, 96, 99, 127–132 Speculative
hypotheses notwithstanding, the use of
dantrolene for the treatment of MDMA
intoxication remains controversial.  The efficacy
of dantrolene in treating this condition has been
questioned, as some patients have improved with
supportive care only133 and some clinicians assert
that there is insufficient evidence to recommend
dantrolene in cases of MDMA acute toxic
reaction.134–136
To determine if MDMA caused an increase of
calcium within the muscle, which would suggest
that an inhibitor of calcium release in skeletal
muscle, such as dantrolene, might be efficacious
in treating MDMA intoxication, in vitro
experiments using human muscle subjected to
halothane and caffeine contracture tests were
performed (used to test for susceptibility to
malignant hyperthermia).  It was hypothesized
that if MDMA raised the calcium levels within
the muscle, then dantrolene should be effective
in treating MDMA acute toxic reaction, since it is
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effective in treating malignant hyperthermia.  The
results indicated that the hyperthermia from
MDMA intoxication is associated with an
elevation in the myoplasmic calcium concen-
trations, similar to that seen in malignant
hyperthermia, which suggests that dantrolene
might be a helpful agent in treating MDMA-
induced hyperthermia.137 It has been argued that
MDMA-induced hyperthermia results from
augmentation of central serotonin, and since
dantrolene has no central activity (inhibits
calcium peripherally in the skeletal muscle), it
should not be effective.  Therefore, a non-
depolarizing neuromuscular blocker may be just
as effective in treating MDMA acute toxic
reaction.92 As stated previously, however,
ventilation and intubation may be required.94
Although, there are not sufficient data in humans
to confirm that the hyperpyrexia associated with
MDMA is a centrally mediated effect, the use of
dantrolene should not be precluded because it
does appear to reduce pyrexia secondary to
exertional heatstroke.138 It is hypothesized that
the unpredictable hyperthermia associated with
MDMA may result from an underlying metabolic
myopathy, similar to that seen with exertional
heatstroke, and associated with a skeletal muscle
abnormality similar to malignant hyperthermia.139 
Cardiovascular Treatment
Tachycardia without hemodynamic
compromise does not need to be treated.
Sedative dosages of benzodiazepines may be
helpful by reducing blood pressure and heart
rate, which may reduce myocardial oxygen
demand.140 b-Blockers should be avoided when
treating stimulant-induced hypertension because
this may result in unopposed a-adrenergic
vasoconstriction.  Hypertension can be treated
with an a-blocker such as phentolamine or with
a direct-acting vasodilator such as nitroprusside.94,
123 Another option is the use of a b-blocker
concurrently with phentolamine.126 Myocardial
ischemia caused by stimulants should be treated
with oxygen, aspirin, and benzodiazepines.  If
these options do not reverse the ischemia, then
vasodilators or phentolamine should be given.102
Arterial spasm may be treated with sublingual or
intravenous nitroglycerin.94 Arrhythmias should
be treated according to advanced cardiac life
support guidelines.123, 126 Thrombolytic agents
have been given safely to patients with stimulant-
induced myocardial infarction.140
Cerebrovascular Treatment
Patients with altered mental status, lethargy, or
obtundation should undergo CT of the brain
because of the risk for intracranial hemorrhage
and infarct.123 In patients with nontraumatic
intracranial hemorrhage, arteriography should be
performed and a thorough history of the use of
illicit substances should be evaluated.105
Neurologic Treatment
Patients who are agitated may require
treatment with a benzodiazepine, such as
diazepam, lorazepam, or midazolam.94, 123 It is
very important to control agitation as this may
decrease further heat production.126 Some of the
conditions associated with MDMA acute toxic
reaction (mental status changes, hyperthermia,
autonomic instability, increased motor
restlessness, myoclonus, elevated creatine kinase
level, diaphoresis, and death due to renal failure)
are similar to the findings in both neuroleptic
malignant syndrome and serotonin syndrome.91,
127 Pharmacologic treatments effective in these
syndromes are recommended by some clinicians,127
including methysergide maleate (nonspecific
serotonin antagonist),141 b-blockers (5-HT1A
antagonists),142 or bromocriptine (a dopamine
agonist).143 However, none of these drugs has
been prospectively evaluated for the treatment of
MDMA acute toxic reaction. 
Caution may be warranted in using
antipsychotic agents when treating MDMA
intoxication.  Antipsychotics decrease the seizure
threshold, and blocking dopamine receptors may
affect the thermoregulatory system leading to
hyperthermia or exacerbation of existing
hyperthermia.  In addition, SSRIs may further
increase serotonergic transmission by blocking
the reuptake of synaptic serotonin, possibly
raising the risk for development of the serotonin
syndrome or aggravating already existing
hyperthermia.144
Hepatotoxicity
Owing to the risk for hepatotoxicity, it would
be prudent to monitor liver function in persons
suspected of taking MDMA,119 and any person
with unexplained jaundice or hepatomegaly
should be screened for a history of MDMA use.93
Treatment will be primarily supportive (see
Supportive Care section).  If severe hepatic
necrosis has occurred, transplantation may be the
only option101 and has been performed
successfully in patients with acute liver failure
due to MDMA use.118
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Supportive Care
Supportive therapy includes rehydration with
intravenous fluids and lowering the temperature
of the patient with use of cooling blankets or ice
baths.143 In some cases, lowering the body
temperature may require infusion of cold
intravenous fluids or peritoneal lavage with cool
dialysate.92 Crystalloids may be given to help
treat both the profuse sweating that often
accompanies MDMA acute toxic reaction as well
as prophylaxis against acute renal failure
secondary to rhabdomyolysis and myoglobinuria.95
Furthermore, judicious fluid support may help
with symptoms of hepatotoxicity as it may
increase liver blood flow and prevent further
hepatic damage.119
Summary
The use of MDMA is on the rise, especially
over the last couple of years.  Although it causes
pleasant sensations, MDMA can be a very
dangerous drug when used recreationally.
Particularly severe adverse reactions include
hyperthermia, rhabdomyolysis, DIC, renal
failure, cardiac complications, intracranial
hemorrhage, and hepatotoxicity.  The long-term
neurotoxic effects, particularly in the
serotonergic system, of MDMA have not been
fully elucidated.  It is imperative that clinicians
be familiar with the symptoms and treatment
options for acute toxic reaction to MDMA.
GHB
History
g-Hydroxybutyric acid (GHB) is a CNS
depressant that has become increasingly popular
as a drug of abuse over the last 10 years.  Many
names are used for GHB such as sodium oxybate,
sodium oxybutyrate, g-hydroxybutyrate sodium,
g-OH, 4-hydroxy butyrate, and g-hydrate, as well
as others.  Names used on the street include
Liquid Ecstasy, Liquid X, Liquid E, Georgia Home
Boy, Grievous Bodily Harm, G-Riffick, Soap,
Scoop, Salty Water, Somatomax, and Organic
Quaalude.  In the 1960s, a French researcher
synthesized GHB in an attempt to create a g-
aminobutyric acid (GABA) analog that would,
unlike GABA, cross the blood-brain barrier.145
Somewhat simultaneously, in 1963, GHB was
found to be a naturally occurring metabolite in
the human brain.146 The first accepted medical
application of GHB was for intravenous
induction of anesthesia.145 However, its use was
limited due to the high frequency of vomiting,147
seizure-like activity in animals,148, 149 and inability
to produce analgesia.150 In the 1970s, GHB was
recommended for narcolepsy because it increases
slow-wave sleep and consolidates sleep at night,
therefore decreasing sleep during the day.151 In
the 1980s, GHB was commonly sold over-the-
counter in health food stores where it was alleged
to increase the effect of growth hormone.152 In
the late 1980s and early 1990s, GHB was
advocated for the treatment of alcohol
dependence153 and opiate withdrawal.154 During
the same time period, GHB was illicitly
advertised as a hypnotic to replace tryptophan,
which had been removed from the market due to
its connection with eosinophilia-myalgia
syndrome.155 Since 1990, an increasing number
of cases of both abuse and toxic reaction has
been noted, and in 1997 GHB was labeled a “date
rape” drug by the press.156 In March 2000, GHB
became a schedule I controlled substance in the
U.S.157
Availability
Most of the GHB available in the U.S. is
manufactured clandestinely.  Many Internet sites
and books that describe the process of making
GHB are available.158 Commonly offered for sale
on Internet sites, GHB kits provide the chemicals
and recipes used to produce GHB.159, 160
Currently, GHB is only legally available in the
U.S. for the investigational treatment of
narcolepsy.  The drug is synthesized by using a
combination of sodium hydroxide and g-
butyrolactone (GBL; another commonly abused
drug).  Because sodium hydroxide is very caustic,
severe toxic reactions may result if GHB is
manufactured improperly.  The drug GHB is
available as a powder or a colorless, odorless
liquid with a salty or soapy taste.  Its taste can
easily be masked by adding it to flavored
beverages.  As GHB is colorless and odorless, and
because small quantities are required to achieve a
desired effect, GHB has been used as a date rape
drug.  The amnesia produced by GHB often
makes victims unable to serve as valid witnesses.
Pharmacokinetics
Pharmacokinetic Parameters
The pharmacokinetics of GHB are nonlinear in
humans over the therapeutic dosage range.161–164
The drug is rapidly absorbed orally,165 with an
onset of action within 15 minutes.166 In the rat,
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oral bioavailability is 52–65%.167 In humans, the
free fraction of GHB in plasma has been shown to
be 0.99, indicating a lack of significant plasma
protein binding.161 The half-life of GHB is 22–28
minutes after an oral dose of GHB 25 mg/kg;161,
162 the half-life is slightly longer with higher
doses.  In one study, GHB exhibited a longer half-
life of 53 minutes in patients with narcolepsy
after dosages of GHB 3.0 g twice/night,
administered 4 hours apart.163 At lower doses of
25 mg/kg, the Tmax of GHB is approximately 30
minutes.  After higher doses of 50 mg/kg, the
Tmax occurs around 45 minutes.161, 162 As the
dose of GHB increases by a factor of four from
12.5 to 50 mg/kg, the AUC increases by a factor
approaching seven.  In addition, the Cmax
increases, but not to the degree expected in
relation to the increase in AUC and the decrease
in oral clearance.  The oral clearance is halved
from 14 to 7 ml/minute/kg when the dose is
increased from 12.5 to 50 mg/kg, respectively.
Two suggested mechanisms for this
nonlinearity include the saturation of one of the
metabolic pathways of GHB or the capacity-
limited absorption of GHB.161 The capacity-
limited absorption would explain the relatively
small increase in Cmax with increasing dose,
relative to the decrease in oral clearance.  It is
possible that several mechanisms operate
concurrently, explaining the pharmacokinetic
profile of GHB.  In one investigation,162 four of
the five subjects exhibiting linear kinetics had
normal liver function test results, whereas all of
the subjects who displayed nonlinear kinetics
(capacity-limited elimination) had elevated
values for some of their liver function tests.  In
the subjects displaying nonlinear kinetics, a
doubling of the dose resulted in a dispropor-
tionate 3-fold increase in the AUC from
approximately 3500 to approximately 10,800
µg/ml/minute.  The appearance of nonlinearity
was found only in the patients who had abnormal
liver function values.  The authors suggest a
relationship between liver function and
saturation of the elimination pathway for GHB.
In addition, when the dose was increased from 25
mg/kg to 50 mg/kg, there were proportional
changes in Cmax, accompanied by dispropor-
tionate increases in AUC.
Metabolism and Synthesis
The biosynthetic pathway and metabolic
degradation of GHB occurs in brain tissue by
means of multiple cytosolic and mitochondrial
enzymes.  g-Hydroxybutyrate is a natural
product of GABA metabolism by way of the
intermediate compound, succinic semialdehyde
(SSA).  The neurotransmitter GABA appears to be
the major precursor for SSA, from which GHB is
synthesized.  In early investigations, it was
shown that GABA underwent transamination to
SSA,168 that the enzymatic reduction of SSA to
GHB occurred in mammalian brain in vitro,169
and that [3H]GABA was converted to GHB in the
rat brain in vivo.170 The finding that GABA is a
precursor of GHB was confirmed by other
investigators.171 The NADPH-dependent enzyme
SSA reductase is responsible for the conversion of
SSA to GHB (Figure 4).171 g-Hydroxybutyrate is
oxidized into SSA by means of GHB dehydro-
genase and GHB-oxoacid transhydrogenase.172
The SSA is further metabolized to succinate,
which then enters the Krebs cycle.173
Elimination
Less than 2% of GHB is eliminated unchanged
in the urine.162, 164 Owing to the short half-life,
there is no accumulation of GHB with repeated
dosing and GHB doses of up to 100 mg/kg are no
longer detectable in the blood from 2–8 hours or
in the urine after 8–12 hours.162, 165 The
variability of these findings may depend on the
sensitivity of the assay used, or it may be due to
interindividual variability.  In summary, it has
been suggested that regardless of the dose given,
the elimination of GHB is so rapid, even in those
with compromised liver function, that the drug is
completely eliminated within 4–6 hours after
ingestion.162
Pharmacology
Receptor Biochemistry
The exact mechanism of GHB action in the
CNS has not been determined, but GHB is
structurally related to GABA (Figure 4), which is
a precursor in GHB formation.170 Much debate
exists regarding whether GHB has neuro-
transmitter or neuromodulatory roles,174–177
because GHB has high-affinity brain receptors
and undergoes synthesis, release, uptake, and
degradation within the CNS.174, 175 The exact
location of the biosynthetic pathway of GHB
inside the cell (cytosol vs mitochondria) has not
been fully established.178 The neurotransmitter
GABA is transaminated by GABA amino-
transferase to form SSA, which is either further
metabolized into succinic acid or reduced to
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form GHB by the enzyme SSA reductase, a
NADPH-dependent enzyme.171, 173 The highest
concentrations of GHB in the brain are found in
the substantia nigra179 and hypothalamus,
whereas the highest turnover rate of GHB occurs
in the hippocampus.180 The uptake of GHB
appears to be the highest in the striatum,181, 182
and this uptake is dependent on a specific
sodium-dependent active transport system for
GHB.181 In addition to being found in the CNS,
GHB is found in the kidney, heart, skeletal
muscle, and brown fat.183
g-Hydroxybutyrate appears to have affinity for
two receptor sites in the CNS.  It binds to GHB
receptors, which may be linked to cyclic
guanosine 3 ¢ 5 ¢ -monophosphate and inositol
phosphate intracellular pathways184, 185 and are
most numerous in the hippocampus and
cortex.186 It also binds to GABAB receptors,187, 188
but not to GABAA receptors.189 The relevance of
this remains unknown but suggests that some of
the pharmacologic actions of GHB are mediated
by the GABAB receptor.
The drug GHB alters dopaminergic activity, in
some cases increasing and in others decreasing
the amount of dopamine released.178 The
systemic administration of GHB to animals
results in increased dopamine accumulation in
the extrapyramidal system of the brain, which
reaches its highest values 1–2 hours after
injection, without parallel increases in serotonin
or norepinephrine.190 The administration of a-
methyltyrosine, which blocks the activity of
tyrosine hydroxylase, almost completely blocks
the rise in brain dopamine induced by GHB,
which occurred within 1 hour in control mice.
Therefore, GHB mediates the accumulation of
dopamine by increasing the activity of tyrosine
hydroxylase.191 In addition, GHB may inhibit the
release of newly synthesized dopamine192 and
decrease the firing rate of dopaminergic neurons
in the substantia nigra with maximal inhibition
within 8 minutes.179 The end result seems to be a
tissue accumulation of dopamine in the brain,175
which is supported by results of the short-term
studies described above.  Dopamine release in the
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Figure 4. Mechanism of GHB elimination.  g-Butyrolactone (GBL) and 1,4-butanediol (1,4-BD) are converted in the body to
GHB.
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striatum may be accompanied by the release of
endogenous opioids.193 The exact interactions
between GHB and the opioid system are not fully
understood, but the administration of naloxone
or nalorphine, opioid receptor antagonists,
blocks some of the effects of GHB.193, 194
Dose-Related Effects
The primary dose-related effects of GHB are
related to CNS depression.  At 10 mg/kg, GHB is
capable of producing amnesia195 and hypotonia of
the skeletal muscles196, 197 resulting from the
depression of neurons in the spinal cord.166 At
20–30 mg/kg, GHB promotes a normal sequence
of rapid eye movement (REM) and non-REM
(slow-wave) sleep, which lasts from 2–3 hours.151,
198 At 40–50 mg/kg intravenously, GHB produces
a state of somnolence, which appears within
5–15 minutes, and an oral dose of approximately
the same amount will produce similar results.166
Anesthesia is associated with doses of 50
mg/kg,164, 166, 199 and doses higher than 50 mg/kg
have been associated with profound coma,199 as
well as decreased cardiac output, respiratory
depression, and seizures.  These effects are more
pronounced with the coingestion of CNS
depressants, particularly ethanol.155 Larger doses
of 60–70 mg/kg produce a state of unarousable
coma that lasts about 1–2 hours.166 The
investigators who initially discovered that GHB
was a natural metabolite of the brain reported
that GHB 100 mg/kg administered intravenously
produced sleep that begins within 15 minutes of
administration and lasts about 1.5–2 hours.146
Serum Concentrations
Oral ingestion of GHB 75–100 mg/kg in
humans results in peak blood levels of
approximately 90–100 µg/ml at 1–2 hours after
ingestion.165 Intravenous administration of GHB
50 and 165 mg/kg results in peak blood levels
that reach 180 and 412 µg/ml, respectively.  The
mean blood GHB level at the commonly used
dose of 100 mg/kg is 304 µg/ml.164 When the
blood GHB levels exceed 258 µg/ml, subjects fall
into a state of deep sleep, characterized by
nonresponse to various stimuli such as touch,
pinprick, deep pressure, skin preparations, or
vaginal examinations, although there is still
reflex response to surgical incision.  During this
stage of deep sleep, blinking stops and the eyes
remain central and fixed with small pupils.  A
moderate level of sleep is associated with blood
GHB levels ranging from 155–258 µg/ml.  This
moderate stage of sleep is characterized by
spontaneous blinking and responses to deep
pressure.  Blood GHB levels ranging from 52–155
µg/ml are associated with a light sleep charac-
terized by spontaneous movements and occasional
opening of the eyes.  When the blood GHB levels
decrease below 52 µg/ml, subjects wake up.164
Abuse Potential and Intoxication
Factors that seem to contribute to the abuse
potential of GHB include its intoxicating effects,
its purported anabolic effects, its hypnotic effects,
and its ability to incapacitate women for
purposes of sexual assault.157, 200, 201 One of the
main reasons GHB became a popular drug of
abuse is its ability to produce a “high.”155, 202
Those who take GHB describe it as producing a
state of relaxation and tranquility accompanied
by feelings of calmness, mild euphoria, a
tendency to verbalize, mild numbing, and
pleasant disinhibition.  Despite these positive
feelings attributed to the use of GHB, the dose-
response curve for GHB has been described as
being remarkably steep.  Therefore, as the dose of
GHB is increased, a steep increase in adverse
effects may occur.143 The effects of GHB have
been described as being similar to those of
alcohol, and the two agents may act syner-
gistically, further increasing the risk for
intoxication or overdose.203
Cardiovascular Effects
Moderate bradycardia appears after the
administration of GHB204, 205 and is likely due to
central vagal activity.166 In addition to
bradycardia, GHB reduces stroke volume as well
as cardiac output, which reaches a nadir around
30 minutes after ingestion.  Atropine reverses the
decreases in both heart rate and stroke volume.205
The autonomic centers are fully active during
GHB-induced coma, and surgical stimuli result in
a cardiovascular response, such as tachycardia,
hypertension, and raised cardiac output.150, 166, 204
Respiration
Respiratory rate is often reduced, but this is
usually accompanied by an increase in tidal
volume.150, 204 The drug GHB also produces a
slowing and deepening of respiration sometimes
leading to a Cheyne-Stokes pattern.166, 204
Neuroendocrine Effects
In an early study that stimulated much interest
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in the use of GHB by the bodybuilding
population, intravenous administration of GHB
2.5 g significantly increased plasma growth
hormone levels, which peaked at 60 minutes.152
In a more recent study, after bedtime oral
ingestion of GHB  2.5, 3.0, and 3.5 g, a
significant increase occurred in the normal
secretory pulse of growth hormone during the
first 2 hours after sleep onset.  The authors
suggest that agents such as GHB may increase the
release of growth hormone by increasing slow-
wave sleep, because there is a large pulse in
growth hormone secretion during the first stage
of slow-wave sleep more than 90% of the time.206
Sedation and Anesthesia
The principal actions of GHB have not been
fully elucidated.  However, the results of early
investigations suggest that GHB appears to act on
the cerebral cortex with little or no depression of
the reticular activating system.150 Some authors
speculate that there is depression of the limbic
hippocampal structures166 and subcortical
centers.199 The anesthetic effects of GHB are
primarily hypnotic204 as GHB provides little or no
analgesia.150, 204 The transition from wakefulness
is described as being a sudden shift from
responsivity to unconsciousness.199
Sleep Physiology
The drug GHB stimulates slow-wave sleep.199,
207–210 It does not appear to suppress REM
sleep207, 209 and may even decrease fragmentation
of REM sleep.208 It appears to increase “slow”
sleep as evidenced by a slow synchronized
electroencephalographic recording.199 In
addition, GHB increases slow-wave sleep (stages
3 and 4), whereas light sleep (stage 1) is
decreased, and the frequency of awakenings is
reduced.210 In healthy subjects, under double-
blind conditions, single oral doses of GHB 2.25 g
significantly increased the time spent in slow-
wave sleep, while sacrificing stage 1 sleep and
significantly decreasing slow-wave sleep latency.
The efficiency of REM sleep is increased, but the
REM latency and time spent in REM sleep do not
change.211
Therapeutic Applications
Most of the therapeutic applications of GHB
result from its sedative and hypnotic effects on
the CNS.  There are no currently accepted
medical applications for GHB in the U.S.,
although it is being evaluated for the symptoms
of narcolepsy.157 However, GHB has been
extensively administered and studied for a variety
of indications in other countries.
Sedation and Anesthesia
The first clinical application of GHB was as a
hypnotic anesthetic agent.145 It is still given for
sedation and anesthesia in Germany, where it is
considered safe and effective as long as the doses
given are limited to the clinical needs.212 In doses
of 10–20 mg/kg, GHB demonstrates hemodynamic
stability and lack of severe respiratory
depression, while control and recovery are
acceptable for clinical purposes.213 However,
bradycardia, hypotension, arrhythmias, and
severe respiratory depression have been reported
during GHB intoxication (see Adverse Effects
section).
Cellular and Cerebral Protection
g-Hydroxybutyrate may be an endogenous
inhibitor of energy metabolism, protecting tissues
when energy supplies are low.  Evidence suggests
that GHB reduces cellular activity, while
depressing the utilization of glucose as well as
other energy substrates.  This may result in
tissues being less sensitive to the damaging
effects of anoxia or during periods of excessive
metabolic demand.  Therefore, the natural
function of GHB may include a role as a tissue
protective substance.214 g-Hydroxybutyrate
reduces tissue oxygenation demands and protects
cells during hypoxic states, which has been
demonstrated in both human and animal studies
as well as in various organ systems.  It exerts a
protective effect and reduces cellular damage
during sepsis, hemorrhagic shock, great vessel or
coronary artery occlusion, stroke, organ
transplantation, and myocardial infarction.  In
addition, in humans with brain tumors, GHB
decreases intracranial pressure and increases
cerebral blood flow.  A thorough review of these
topics involving the cellular protective effects and
cerebral protective effects of GHB, as well as
various applications for GHB in anesthesia, has
been published.215
Narcolepsy and Insomnia
Owing to the ability of GHB to increase slow-
wave sleep and facilitate REM sleep efficiency,
GHB may improve nighttime sleep and therefore
improve alertness during the day, which could
alleviate some of the symptoms of narcolepsy.151,
208–210, 216 In addition, administration of GHB to
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patients with narcolepsy revealed significant
improvements in sleep attacks, daytime
drowsiness, cataplexy, hypnogogic hallucinations,
and sleep paralysis.209, 217 Because GHB is a CNS
depressant, it has been investigated for treating
the symptoms of insomnia,165, 207 and in one
investigation it was rated by the subjects as being
an “excellent hypnotic.”165 However, when being
used as a hypnotic, an oral dose of GHB 100
mg/kg resulted in frequent awakenings at either
1.5 or 4–5 hours after ingestion, which
accounted for 14 of the 25 adverse effects
reported in this dose group.165 Furthermore,
GHB reportedly produced sleep paralysis, sleep
walking, and cataplexy.151
Alcohol and Opiate Withdrawal
The drug GHB 50 mg/kg/day has been given
orally to treat the symptoms of acute alcohol
withdrawal and to facilitate both short- and long-
term abstinence from alcohol.  It also was given
to treat opiate withdrawal, often in higher
dosages of 50–300 mg/kg/day.  These applications
of GHB were discussed extensively in a recent
review of this topic during a symposium hosted
by the Italian Society on Biological Psychiatry.218
Despite a possible benefit of taking GHB for these
conditions, craving for GHB developed during
these trials, with some subjects increasing their
dosage up to 6-7 times the recommended
levels.219
Anabolism
Although GHB is commonly taken for its
proposed anabolic effects (related to the ability of
GHB to stimulate the release of growth
hormone), especially by the bodybuilding
community,152, 206, 220 no definitive evidence exists
that it increases muscle mass or fat catabolism.
In addition, in patients with chronic alcoholism,
long-term administration of GHB did not affect
muscular mass.221
Adverse Effects and Acute Toxic Reactions
Acute Syndrome
The Centers for Disease Control and Prevention
(CDC) released two reports describing the toxic
effects of GHB.155, 222 These reports document
over 120 poisonings and one fatality in
individuals from various regions of the U.S. who
became ill secondary to taking GHB.  The usual
course of illness was very similar from case to
case.  Approximately 15–60 minutes after
ingestion, one or more of the following
symptoms occurred:  vomiting, drowsiness,
soporific state, hypotonia, or vertigo.  Depending
on the dosage taken and concurrent use of other
CNS depressants, such as alcohol, any of the
following occurred as well:  loss of consciousness,
respiratory depression, tremors, myoclonus,
seizure-like activity, bradycardia, hypotension, or
respiratory arrest.  In many of these cases, the
symptoms spontaneously resolved within 2–96
hours.155, 222 As a result of the increased rate of
GHB abuse since the first CDC report in 1990,
the number of acute intoxications due to GHB
has increased.158, 160, 200, 202, 222–235 Some of the
more common and better documented conditions
that appear in various reports include coma,
respiratory depression, seizure-like activity
(uncontrollable or unusual movements),
bradycardia, drowsiness or dizziness, confusion,
amnesia, headache, nausea, vomiting, mild
hypothermia, acidosis, and psychiatric
complications (e.g., agitation, delirium).
Since 1992, the DEA has documented over
9600 adverse reactions, overdoses, and other
cases reported by various law enforcement
agencies, poison control centers, and hospitals in
46 states.157 The Food and Drug Administration
has issued warnings to inform consumers about
the dangers of ingesting two potentially
dangerous GHB precursors, g-butyrolactone
(GBL) and 1,4 butanediol (BD), which are
converted to GHB in the body.236, 237 The doses of
GHB that elicit adverse effects vary greatly from
report to report and range from 0.25 teaspoon
(1.25 ml) to 4 tablespoons (60 ml)200 up to 16
ounces (480 ml).223 However, GHB often is
produced in clandestine laboratories, resulting in
preparations with a wide range of purity and
strength.  Therefore, the quantities reported to be
ingested in cases of acute intoxications may not
be that informative.  A 99% pure sample of GHB
weighs 2.8 g/level teaspoon (5 ml).200 However,
40 ml of clandestinely produced GHB may weigh
from 3–20 g.224 One aspect of GHB that makes it
dangerous is that the response to oral ingestion
seems to vary within the same patient as well as
between patients.
The adverse effects described in the following
sections were found in experimental investigations
and in reports of intoxications.  The drug GHB
affects the CNS, cardiovascular system, and
respiratory system but does not have a toxic
effect on the kidneys or the liver.151, 166
CNS Effects
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Drowsiness and dizziness induced by GHB are
reported frequently in both investigational and
toxicity reports.  Subjects receiving oral doses of
GHB 25–50 mg/kg in a controlled study
complained of dizziness and drowsiness.161
Other common CNS adverse effects include
vertigo and headache.165 More serious CNS
depression during intoxication with GHB
commonly occurs.  Numerous reports of
intoxication with GHB describe patients who
present with Glasgow Coma Scale (GCS) scores
as low as 3–5.224–231 Recovery appears to be
inversely related to GCS score, with a lower GCS
score resulting in a longer time to recover.228
Coma induced by GHB usually appears rapidly
after ingestion, followed by a rapid and apparent
full recovery.  Often in the cases of intoxication,
the unconsciousness will resolve within 6–7
hours.200, 223, 225–230, 232 One of the distinctively
characteristic aspects of GHB intoxication is the
rapid recovery, which is often uneventful and
may create a false sense of security in the user.223
Cardiovascular Effects
Bradycardia has occurred when GHB was given
for anesthesia150, 166, 204 as well as in overdose
situations.200, 222, 224, 228, 231 In a retrospective
review of GHB intoxication, 36% of patients had
pulse rates defined as bradycardia (heart rate
< 55 beats/minute) and one patient required a
single dose of atropine for a heart rate of 24
beats/minute.228 In the same case series, 10
patients had hypotension (systolic blood pressure
≤ 90 mm Hg) at presentation.  Six of the patients
with hypotension also had concurrent bradycardia,
and in all six cases alcohol and/or another drug
of abuse were present.  In another case series of
seven patients, the authors reported that five
patients developed U waves on their electro-
cardiograms after GHB exposure, although none
of them was significantly hypokalemic.  Three of
these five patients had significant abnormalities
that included first-degree heart block, right
bundle branch block, and ventricular ectopy.233
Respiratory System
Respiratory depression, difficulty breathing,
and apnea have been reported after the
administration of GHB.155, 166, 200, 202, 222, 224, 228, 231,
233, 235 The respiratory depression may be very
severe, and in some cases the respiratory rate
may drop to as low as four breaths/minute.224, 231
Abnormal patterns of breathing such as Cheyne-
Stokes breathing may result.204
Psychopathology
Under the influence of GHB, some individuals
may become hostile, belligerent, and agitated.223,
225 Patients display loss of consciousness and are
extremely combative when stimulated, despite
profound respiratory depression.  Furthermore,
they may require physical restraints to protect
themselves and hospital personnel.233 Psychiatric
complications such as delirium, paranoia,
depression, and hallucinations have been
reported in a small number of patients.158, 234
Ocular Effects
During intoxication with GHB, the pupils have
been described as being miotic and sluggishly
reactive to light,225 and during coma induced by
GHB the eyes have been found to be miotic and
unresponsive to light.199
Acidosis
Mild acute respiratory acidosis is a common
finding when GHB has been used as an
anesthetic, as well as when it has been abused.228,
233 In one review, 93% of patients had a pH less
than 7.40, and 30% had a pH less than 7.30.  In
addition, 70% of patients had a partial pressure of
carbon dioxide of 45 mm Hg or greater.228
Gastrointestinal System
A high frequency of vomiting is associated with
the use of GHB,147, 238 especially during induction
and on emergence from intravenously induced
anesthesia.166, 238 In an early investigation, 52% of
patients receiving GHB for anesthesia
experienced nausea or vomiting.204 According to
one case series, vomiting was also very common
and occurred in 30% of 88 cases of GHB
intoxication.  It typically occurred as the patients
were regaining consciousness.228 In another
review of 78 cases of GHB overdose, vomiting
was reported in 22% of the cases.229
Body Temperature
Although hypothermia has not been a
universal finding during GHB intoxication,233
mild hypothermia has been observed in patients
after a GHB overdose.223, 225, 227, 228 In one study of
70 patients, 31% had an initial body temperature
of less than 35°C, and the mean body
temperature was 35.8 ± 1.1°C.228 In an additional
small series of five patients, hypothermia was
reported in three patients, with the lowest
temperature being 32.8°C.227
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Movements
There have been many reports of unusual,
random clonic movements and uncontrollable
shaking associated with GHB use.150, 155, 166, 200, 202,
225, 227, 229, 234, 235 In anesthesia studies, abnormal
movements occurred during induction with GHB
but were not accompanied by any seizure-like
electroencephalographic tracings and could be
reduced by administering a phenothiazine
drug.150 Administration of GHB will not
necessarily result in abnormal epileptiform
electroencephalographic changes212 or seizure-
like activity.228
Miscellaneous
Cold and heavy extremities have been reported
after oral ingestion of GHB 50 mg/kg.165
Diaphoresis was reported in 35% of the 78 cases
of GHB overdose in one investigation.229 Home
brewing of GHB, often from kits sold on Internet
sites or from mail order sources, can lead to
various adverse effects due to improper
manufacturing of GHB.  The manufacture of GHB
involves the mixture of g-butyrolactone and the
alkaline substance, sodium hydroxide.  The
inappropriate manufacture of GHB may lead to a
very alkaline mixture, resulting in esophageal
damage.239 In New York, a 20-year-old man
aspirated during vomiting, resulting in damage to
his lung tissue that was attributed to the mixture
of gastric contents containing sodium hydroxide.222
Hematuria has also occurred after the ingestion
of improperly manufactured GHB.  Home-brewed
GHB was being made with swimming pool
chlorine tablets instead of the required sodium
hydroxide.159
Withdrawal and Tolerance
Data gathered by the DEA indicate that those
who take GHB have exhibited chronic self-
administration, compulsive abuse regardless of
adverse consequences, as well as drug-seeking
behaviors.  These data suggest individuals may
become psychologically dependent on GHB.157
Physical dependence may develop, with a
withdrawal syndrome occurring on abrupt
discontinuation.157, 201, 240–242 Tolerance to the
effects of GHB results in an increase in dosage
and a withdrawal syndrome on cessation of GHB
ingestion.201, 241–243 The withdrawal syndrome is
characterized by insomnia, tremor, and anxiety
that may last approximately 1 week.201 In
addition, more severe symptoms have been
reported, including confusion, hallucinations,
delirium, and autonomic stimulation with
tachycardia.  The symptoms of withdrawal may
begin within 1–6 hours after the last dose of GHB
and may last from 5–15 days.242
One case of Wernicke-Korsakoff syndrome has
been attributed to the use of GHB.244 According
to the authors, the patient had not imbibed
alcohol for several months before admission,
although there was no mention of an ethanol
screen.  The patient presented with the classic
triad of symptoms of Wernicke-Korsakoff
syndrome:  global confusion, sixth nerve palsies,
and ataxic gait.  In addition, paranoid delusions
and hallucinations were present.  According to
the authors, the atypical mental features
represented GHB withdrawal and were similar, in
part, to delirium tremens without the serious
autonomic dysfunction.  The patient’s symptoms
resolved quickly with thiamine treatment, with
the eye movement abnormalities resolving
rapidly, followed by resolution of the abnormal
gait and mentation.244 The clinical picture of
GHB withdrawal appears to range from anxiety,
tremor, and insomnia to more severe symptoms
such as disorientation, paranoia, hallucinations,
tachycardia, and possibly extraocular motor
impairment.
Death
Fatalities have been associated with GHB
use.157, 222, 245–247 The DEA has collected inves-
tigative, toxicology, and autopsy reports from
cases in which GHB was found in biological
samples of the deceased.  Since 1990, the DEA
reports that they are aware of 68 deaths
associated with the use of GHB, most of which
have occurred in the last 4 years.  Details of the
cases are not given.157 In an article discussing
pre- and postmortem GHB blood and urine
levels, the authors refer to four fatalities
attributed to the use of GHB.246 Three of the
fatalities had postmortem  blood GHB levels
ranging from 52–121 mg/L.  In a series of
forensic samples submitted for laboratory
analysis, blood GHB levels ranging from 3.2–168
mg/L were found in 15 of 20 autopsy specimens,
although the deaths were not thought to be GHB
related.  Furthermore, GHB was not found in
samples from living subjects who did not take
GHB.  Because of these findings, the authors
suggest that GHB may be a natural product of
postmortem decomposition occurring in blood.246
Other investigators suggest that the magnitude of
GHB levels found in many fatality cases is too signif-
icant to be attributed to postmortem decomposition.247
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Treatment
Resuscitation
The mainstay of treatment for GHB
intoxication is protection of the airway and
assisted ventilation if needed.  Intubation, to
protect the airway, is a common treatment
procedure during GHB intoxication, and assisted
ventilation may be required in some cases.233, 248
Laboratory monitoring should include serum
electrolytes and blood glucose levels in
symptomatic patients, and additional monitoring,
such as pulse oximetry and arterial blood gases,
in patients with respiratory depression.  Because
of the increased prevalence of GHB abuse, it
should be considered as a causal agent in any
patient with coma of unknown origin at
presentation.  Since GHB is rapidly cleared from
the body, it is often difficult to confirm the
definite use of GHB.  Furthermore, GHB will be
missed by many conventional first-line urine
drug screens,249 and analysis with gas
chromatography mass spectrometry is required
for detection and quantification.250 Therefore, a
history from the patient, or others who witnessed
the GHB use, may be important diagnostic
information.  However, because GHB has
amnestic properties, the patient may not be able
to provide a very reliable history.  Some suggest
that a history of bodybuilding or athletic
physique may aid in the diagnosis of GHB
abuse,158, 226 as this drug is commonly used in this
patient population.
Decontamination and Elimination
The roles of gastric lavage and activated
charcoal have been questioned as the volumes of
GHB are very small and GHB is rapidly absorbed
from the gut,251 but these treatments may be
helpful when GHB is coingested with other drugs
of abuse.  Activated charcoal may be of benefit
for recent, large ingestions of GHB.252 Induction
of emesis is not recommended because the CNS
depression and diminished gag reflex may lead to
pulmonary aspiration.252
Neurologic Treatment
Because many of the symptoms of GHB
intoxication are so rapidly reversed, it is difficult
to determine if purported helpful pharmacologic
treatments have been successful or if the GHB
intoxication has simply worn off.  In clinical cases
of GHB intoxication, both naloxone and
flumazenil have been found to be of no benefit in
reversing unconsciousness.155, 200, 223–225, 230, 231, 233, 234
Owing to the association between GHB and
absence epilepsy in animals, various
anticonvulsant agents have been used as GHB-
reversal agents, but there are no data in the
literature indicating that any of these agents have
been useful in experimental or clinical situations
in humans.  Monitoring neurologic function and
applying GCS scores are essential.  Patients with
an initial GCS of 8 or less may have a more
serious clinical course, requiring a longer
recovery time, so they should be monitored very
closely.228 It has been suggested that if a patient
has stable mental status and vital signs after 6
hours of observation in the emergency
department, he or she could be discharged unless
there is some other indication for hospital
admission.233
Case reports231 and clinical trials253–255 indicate
that neostigmine or physostigmine may be
helpful in the treatment of the symptoms of GHB
intoxication.  Physostigmine is given clinically to
reverse the toxic CNS effects caused by
anticholinergic agents.  Three trials in humans
undergoing GHB anesthesia have evaluated the
use of physostigmine or neostigmine as reversal
agents.253–255 Two of these studies included the
use of a neuromuscular blocker in addition to
GHB, which complicate the results.  In one study,
effective reversal of GHB-induced sedation
occurred after the administration of
physostigmine alone, given intravenously as 2-
mg single or repeated doses.253
Cardiovascular Treatment
Symptomatic bradycardia associated with GHB
intoxication should be treated with atropine.230,
233 However, although a single case report
indicated that atropine was successful in treating
a case of severe bradycardia,228 this approach has
not been adequately evaluated.
Withdrawal
Benzodiazepines may be given to treat the GHB
withdrawal syndrome.252 In one reported case,
the withdrawal symptoms were so severe that,
over a 9-day detoxification period, the patient
received propranolol, benzodiazepines, and
phenothiazines for paranoia, agitation, and
delirium.241 In another report, the patient
displayed agitation, hallucinations, tachycardia,
and elevated blood pressure after the cessation of
GHB.  Over the course of this patient’s treatment,
he received lorazepam 507 mg and diazepam 120
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mg for agitation over a 90-hour period.243
Although benzodiazepines and other agents have
been given to treat the signs and symptoms of
GHB withdrawal, no standard treatment protocol
exists.
Supportive Care
The treatment of GHB intoxication is mainly
supportive because no specific GHB antidote has
been proved effective in humans.  Because of
reduced respiratory function, the patient may
require intubation or mechanical ventilation.  As
vomiting is a common symptom of GHB
intoxication, airway protection becomes even
more important to avoid the risk of aspiration.
The improper manufacture of GHB can lead to a
mixture of GHB and sodium hydroxide, which is
very caustic and, if aspirated, is likely to cause
severe damage to the lung tissue.  Therefore, it is
important to maintain the airway and establish
intravenous access.
Conclusion
The use of MDMA and GHB has risen
dramatically over the last couple of years.
Evidence indicates that MDMA is toxic to
serotonergic neurons in animals.  Further
evidence indicates that MDMA may be a
neurotoxin in humans as well.
The drug MDMA is the most popular of the
club drugs and continues to gain popularity
despite adverse effects that have been associated
with it, such as agitation, tachycardia,
hypertension, dilated pupils, trismus, bruxism,
sweating, hyperthermia, DIC, rhabdomyolysis,
and acute renal failure.  Hyperthermia appears to
be the most serious complication, sometimes
leading to a cascade of events including DIC,
rhabdomyolysis, and acute renal failure.
No standard protocols exist for treating MDMA
intoxication.  However, the most important
techniques include lowering the body
temperature and maintaining adequate hydration
to avoid acute renal failure due to rhabdomyolysis
and myoglobinuria.  The cases of hyponatremia
associated with MDMA that have resulted in
seizures, coma, and cerebral edema indicate that
it is extremely important to avoid overhydration
of the patient during treatment.
The use of GHB, although not as popular as
MDMA, is also a significant problem.  It is used
for its sedating, intoxicating, and alleged
bodybuilding properties.  In addition, in recent
years, GHB has been used to facilitate sexual
assault and has been labeled a “date rape” drug
by the press.  Regardless of the initial motive for
using GHB, it is a dangerous substance when
used outside of a controlled setting.  It may cause
acute toxic reactions and possibly physical
dependence, especially if used at high doses for a
prolonged period of time.  Acute symptoms of a
GHB toxic reaction include coma (often with a
GCS score < 8), respiratory depression, seizure-
like activity, bradycardia, drowsiness, confusion,
amnesia, nausea, vomiting, mild hypothermia,
acidosis, and psychiatric complications.
Symptoms associated with acute withdrawal in
those who are physically dependent range from
anxiety, tremor, and insomnia in milder cases, to
confusion, delirium, and hallucinations in more
severe cases.
No standard treatment protocols exist for GHB
intoxication or withdrawal.  However,
physostigmine has been suggested as a possible
treatment option to reduce the CNS and
respiratory depression induced by GHB.
Atropine may be beneficial in cases of severe
bradycardia.  Benzodiazepines are commonly
given for GHB withdrawal symptoms; although,
to our knowledge no prospective studies have
evaluated their use for this indication.
Because of the increasing popularity of club
drugs and their dangerous adverse effects, health
care professionals must be familiar with these
substances.  Early identification and treatment of
symptoms associated with these agents is of
paramount importance.  No standard treatment
protocols exist for the intoxication syndromes
associated with MDMA or GHB, and supportive
care is currently the standard of treatment.
Pharmacologic treatments have been given
successfully for treating the symptoms associated
with MDMA and GHB toxic reactions.  However,
larger clinical trials evaluating the use of
pharmacotherapy during intoxication with, or
withdrawal from, either of these agents are
lacking.  A knowledge of the expected adverse
effects and the course and duration of
intoxication or withdrawal will help health care
providers to identify and treat the consequences
of MDMA or GHB abuse.
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